カテゴリ： Allied Market Research, 世界, 医療/バイオ

認知症治療薬のグローバル市場（2021〜2031）：レビー小体型認知症、パーキンソン病認知症、アルツハイマー病、血管性認知症、その他

■ 英語タイトル：Dementia Drugs Market By Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), By Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB162）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB162
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：265
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[認知症治療薬のグローバル市場（2021〜2031）：レビー小体型認知症、パーキンソン病認知症、アルツハイマー病、血管性認知症、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に8662.17百万ドルであった世界の認知症治療薬市場規模が、2031年までに19704.27百万ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）8.5%で成長すると予測しています。本レポートは、認知症治療薬の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、適応症別（レビー小体型認知症、パーキンソン病認知症、アルツハイマー病、血管性認知症、その他）分析、薬物クラス別（コリンエステラーゼ阻害剤、NMDA 拮抗薬・併用薬）分析、流通チャネル別（小売薬局、病院薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、apotex inc.、Aurobindo Pharma Ltd、Biogen Idec、Eisai、Eli Lilly and Company、Johnson & Johnson、Abbvie Inc、, F. Hoffmann-La Roche AG、Teva Pharmaceutical Industries、Novartis AGなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界の認知症治療薬市場規模：適応症別
- レビー小体型認知症における市場規模
- パーキンソン病認知症における市場規模
- アルツハイマー病における市場規模
- 血管性認知症における市場規模
- その他における市場規模
・世界の認知症治療薬市場規模：薬物クラス別
- コリンエステラーゼ阻害剤における市場規模
- NMDA 拮抗薬・併用薬における市場規模
・世界の認知症治療薬市場規模：流通チャネル別
- 小売薬局チャネルの市場規模
- 病院薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の認知症治療薬市場規模：地域別
- 北米の認知症治療薬市場規模
- ヨーロッパの認知症治療薬市場規模
- アジア太平洋の認知症治療薬市場規模
- 中南米・中東・アフリカの認知症治療薬市場規模
・企業状況
・企業情報

世界の認知症治療薬市場は、2021年に8億6,621万ドルを占め、2022年から2031年にかけて年平均成長率8.5%を記録し、2031年には1億9,704万7,000ドルに達すると予測されています。

認知症は、思考、行動、記憶、日常生活能力の低下が見られる症候群です。認知症の最も一般的な形態はアルツハイマー病です。認知症は、主にまたは二次的に脳に影響を与える多くの傷害や疾患から生じます。認知症に対する認識が不足しているため、検査やケアに支障をきたしています。コリンエステラーゼ阻害薬は、最も一般的に処方される薬で、アセチルコリンが学習、記憶、個人の気分に不可欠であるため、脳内のアセチルコリンの分解を防ぐのに役立ちます。

認知症治療薬市場は、アルツハイマー病の有病率の増加、医薬品開発のための研究開発活動の進展、早期診断の普及などにより、予測期間中に大きく成長すると予測されています。加えて、高齢者人口の増加、研究開発への各社の投資の増加、強力なパイプライン候補の存在、医療インフラ整備への支出の増加、発展途上地域における疾病予防に関する国民の意識の高まり、個別化医療に対する需要の急増などが、市場の成長をさらに促進します。しかし、製品承認に関連する政府の厳しい規制や研究開発活動に関連する高コストが市場成長の妨げになると予想されます。対照的に、創薬技術における技術進歩の加速や、医薬品開発のための政府による高額の投資は、業界に新たな道筋を示す要因であり、認知症治療薬市場に大きな成長機会をもたらすと予想されます。

認知症治療薬市場は、疾患、薬剤クラス、流通チャネル、地域によって区分されます。疾患別では、レビー小体型認知症、パーキンソン病認知症、アルツハイマー病、血管性認知症、その他の適応症に分類されます。薬剤クラス別では、コリンエステラーゼ阻害薬、NMDA拮抗薬およびその配合剤に分類されます。販売チャネル別では、病院薬局、小売薬局、オンライン薬局に分類されます。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他の欧州地域）、アジア太平洋地域（日本、中国、オーストラリア、インド、韓国、その他のアジア太平洋地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他のLAMEA地域）に市場を分けて分析しています。

本レポートでは、世界の認知症治療薬市場で事業を展開する主要企業を包括的に分析しています。本レポートに掲載されている主要企業は、AbbVie Inc.、APPOTEX Inc.、Aurobindo Pharma Limited、Biogen Idec Inc.、EISAI GLOBAL、Eli Lilly and company、F. Hoffmann-La Roche Ltd.、Johnson & Johnson、Novartis AG、Teva Pharmaceuticalsなどです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までの認知症治療薬市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析します。
2021年から2031年までの認知症治療薬市場分析の定量的分析から、・認知症治療薬の市場機会を特定します。
主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を下し、サプライヤーとバイヤーのネットワークを強化できるようにします。
・認知症治療薬市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・認知症治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
疾患別
レビー小体型認知症
パーキンソン病認知症
アルツハイマー病
血管性認知症
その他

薬剤クラス別
コリンエステラーゼ阻害薬
NMDA拮抗薬＆その配合剤

販売チャネル別
小売薬局
病院薬局
オンライン薬局

地域別
・北米
アメリカ
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
中国
日本
インド
韓国
オーストラリア
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
apotex inc.
Aurobindo Pharma Ltd
Biogen Idec
Eisai
Eli Lilly and Company
Johnson & Johnson
Abbvie Inc
F. Hoffmann-La Roche AG
Teva Pharmaceutical Industries
Novartis AG

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION
4.1 Overview
4.1.1 Market size and forecast
4.2 Lewy Body Dementia
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Parkinsons Disease Dementia
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Alzheimers Disease
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
4.5 Vascular Dementia
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market share analysis by country
4.6 Other Indications
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market share analysis by country
CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS
5.1 Overview
5.1.1 Market size and forecast
5.2 Cholinesterase Inhibitors
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 NMDA Antagonists and its Combination Drugs
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Retail Pharmacies
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market share analysis by country
6.3 Hospital Pharmacies
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market share analysis by country
6.4 Online Pharmacies
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market share analysis by country
CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Indication
7.2.3 North America Market size and forecast, by Drug Class
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Key market trends, growth factors and opportunities
7.2.5.1.2 Market size and forecast, by Indication
7.2.5.1.3 Market size and forecast, by Drug Class
7.2.5.1.4 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Key market trends, growth factors and opportunities
7.2.5.2.2 Market size and forecast, by Indication
7.2.5.2.3 Market size and forecast, by Drug Class
7.2.5.2.4 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Key market trends, growth factors and opportunities
7.2.5.3.2 Market size and forecast, by Indication
7.2.5.3.3 Market size and forecast, by Drug Class
7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Indication
7.3.3 Europe Market size and forecast, by Drug Class
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Key market trends, growth factors and opportunities
7.3.5.1.2 Market size and forecast, by Indication
7.3.5.1.3 Market size and forecast, by Drug Class
7.3.5.1.4 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Key market trends, growth factors and opportunities
7.3.5.2.2 Market size and forecast, by Indication
7.3.5.2.3 Market size and forecast, by Drug Class
7.3.5.2.4 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Key market trends, growth factors and opportunities
7.3.5.3.2 Market size and forecast, by Indication
7.3.5.3.3 Market size and forecast, by Drug Class
7.3.5.3.4 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Key market trends, growth factors and opportunities
7.3.5.4.2 Market size and forecast, by Indication
7.3.5.4.3 Market size and forecast, by Drug Class
7.3.5.4.4 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Key market trends, growth factors and opportunities
7.3.5.5.2 Market size and forecast, by Indication
7.3.5.5.3 Market size and forecast, by Drug Class
7.3.5.5.4 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Key market trends, growth factors and opportunities
7.3.5.6.2 Market size and forecast, by Indication
7.3.5.6.3 Market size and forecast, by Drug Class
7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Indication
7.4.3 Asia-Pacific Market size and forecast, by Drug Class
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 China
7.4.5.1.1 Key market trends, growth factors and opportunities
7.4.5.1.2 Market size and forecast, by Indication
7.4.5.1.3 Market size and forecast, by Drug Class
7.4.5.1.4 Market size and forecast, by Distribution Channel
7.4.5.2 Japan
7.4.5.2.1 Key market trends, growth factors and opportunities
7.4.5.2.2 Market size and forecast, by Indication
7.4.5.2.3 Market size and forecast, by Drug Class
7.4.5.2.4 Market size and forecast, by Distribution Channel
7.4.5.3 India
7.4.5.3.1 Key market trends, growth factors and opportunities
7.4.5.3.2 Market size and forecast, by Indication
7.4.5.3.3 Market size and forecast, by Drug Class
7.4.5.3.4 Market size and forecast, by Distribution Channel
7.4.5.4 South Korea
7.4.5.4.1 Key market trends, growth factors and opportunities
7.4.5.4.2 Market size and forecast, by Indication
7.4.5.4.3 Market size and forecast, by Drug Class
7.4.5.4.4 Market size and forecast, by Distribution Channel
7.4.5.5 Australia
7.4.5.5.1 Key market trends, growth factors and opportunities
7.4.5.5.2 Market size and forecast, by Indication
7.4.5.5.3 Market size and forecast, by Drug Class
7.4.5.5.4 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Key market trends, growth factors and opportunities
7.4.5.6.2 Market size and forecast, by Indication
7.4.5.6.3 Market size and forecast, by Drug Class
7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Indication
7.5.3 LAMEA Market size and forecast, by Drug Class
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Key market trends, growth factors and opportunities
7.5.5.1.2 Market size and forecast, by Indication
7.5.5.1.3 Market size and forecast, by Drug Class
7.5.5.1.4 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Key market trends, growth factors and opportunities
7.5.5.2.2 Market size and forecast, by Indication
7.5.5.2.3 Market size and forecast, by Drug Class
7.5.5.2.4 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Key market trends, growth factors and opportunities
7.5.5.3.2 Market size and forecast, by Indication
7.5.5.3.3 Market size and forecast, by Drug Class
7.5.5.3.4 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Key market trends, growth factors and opportunities
7.5.5.4.2 Market size and forecast, by Indication
7.5.5.4.3 Market size and forecast, by Drug Class
7.5.5.4.4 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 apotex inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Aurobindo Pharma Ltd
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Biogen Idec
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Eisai
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Johnson & Johnson
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Abbvie Inc
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 , F. Hoffmann-La Roche AG
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Teva Pharmaceutical Industries
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Novartis AG
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 2. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. DEMENTIA DRUGS MARKET FOR LEWY BODY DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. DEMENTIA DRUGS MARKET FOR PARKINSONS DISEASE DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 7. DEMENTIA DRUGS MARKET FOR ALZHEIMERS DISEASE, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 8. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 9. DEMENTIA DRUGS MARKET FOR VASCULAR DEMENTIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 10. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. DEMENTIA DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 13. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 14. DEMENTIA DRUGS MARKET FOR CHOLINESTERASE INHIBITORS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 15. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 16. DEMENTIA DRUGS MARKET FOR NMDA ANTAGONISTS AND ITS COMBINATION DRUGS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 18. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 19. DEMENTIA DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 21. DEMENTIA DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 22. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 23. DEMENTIA DRUGS MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 24. DEMENTIA DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 25. NORTH AMERICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 26. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 27. NORTH AMERICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. NORTH AMERICA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. U.S. DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 30. U.S. DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 31. U.S. DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 32. CANADA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 33. CANADA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 34. CANADA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. MEXICO DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 36. MEXICO DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 37. MEXICO DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 38. EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 39. EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 40. EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. EUROPE DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 42. GERMANY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 43. GERMANY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 44. GERMANY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. FRANCE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 46. FRANCE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 47. FRANCE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. UK DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 49. UK DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 50. UK DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ITALY DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 52. ITALY DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 53. ITALY DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. SPAIN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 55. SPAIN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 56. SPAIN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 57. REST OF EUROPE DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 58. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 59. REST OF EUROPE DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 60. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 61. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 62. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. CHINA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 65. CHINA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 66. CHINA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. JAPAN DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 68. JAPAN DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 69. JAPAN DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. INDIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 71. INDIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 72. INDIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. SOUTH KOREA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 74. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 75. SOUTH KOREA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 76. AUSTRALIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 77. AUSTRALIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 78. AUSTRALIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 79. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 80. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 81. REST OF ASIA-PACIFIC DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 82. LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 83. LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 84. LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 85. LAMEA DEMENTIA DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 86. BRAZIL DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 87. BRAZIL DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 88. BRAZIL DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 89. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 90. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 91. SAUDI ARABIA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 92. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 93. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 94. SOUTH AFRICA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 95. REST OF LAMEA DEMENTIA DRUGS MARKET, BY INDICATION, 2021-2031 (REVENUE, $MILLION)
TABLE 96. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 97. REST OF LAMEA DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 98.APOTEX INC.: COMPANY SNAPSHOT
TABLE 99.APOTEX INC.: OPERATING SEGMENTS
TABLE 100.APOTEX INC.: PRODUCT PORTFOLIO
TABLE 101.APOTEX INC.: NET SALES
TABLE 102.APOTEX INC.: KEY STRATERGIES
TABLE 103.AUROBINDO PHARMA LTD: COMPANY SNAPSHOT
TABLE 104.AUROBINDO PHARMA LTD: OPERATING SEGMENTS
TABLE 105.AUROBINDO PHARMA LTD: PRODUCT PORTFOLIO
TABLE 106.AUROBINDO PHARMA LTD: NET SALES
TABLE 107.AUROBINDO PHARMA LTD: KEY STRATERGIES
TABLE 108.BIOGEN IDEC: COMPANY SNAPSHOT
TABLE 109.BIOGEN IDEC: OPERATING SEGMENTS
TABLE 110.BIOGEN IDEC: PRODUCT PORTFOLIO
TABLE 111.BIOGEN IDEC: NET SALES
TABLE 112.BIOGEN IDEC: KEY STRATERGIES
TABLE 113.EISAI: COMPANY SNAPSHOT
TABLE 114.EISAI: OPERATING SEGMENTS
TABLE 115.EISAI: PRODUCT PORTFOLIO
TABLE 116.EISAI: NET SALES
TABLE 117.EISAI: KEY STRATERGIES
TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 121.ELI LILLY AND COMPANY: NET SALES
TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
TABLE 123.JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 124.JOHNSON & JOHNSON: OPERATING SEGMENTS
TABLE 125.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 126.JOHNSON & JOHNSON: NET SALES
TABLE 127.JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 128.ABBVIE INC: COMPANY SNAPSHOT
TABLE 129.ABBVIE INC: OPERATING SEGMENTS
TABLE 130.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 131.ABBVIE INC: NET SALES
TABLE 132.ABBVIE INC: KEY STRATERGIES
TABLE 133., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 134., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 135., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 136., F. HOFFMANN-LA ROCHE AG: NET SALES
TABLE 137., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 138.TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT
TABLE 139.TEVA PHARMACEUTICAL INDUSTRIES: OPERATING SEGMENTS
TABLE 140.TEVA PHARMACEUTICAL INDUSTRIES: PRODUCT PORTFOLIO
TABLE 141.TEVA PHARMACEUTICAL INDUSTRIES: NET SALES
TABLE 142.TEVA PHARMACEUTICAL INDUSTRIES: KEY STRATERGIES
TABLE 143.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 144.NOVARTIS AG: OPERATING SEGMENTS
TABLE 145.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 146.NOVARTIS AG: NET SALES
TABLE 147.NOVARTIS AG: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 認知症治療薬の世界市場2023～2028：疾患別（レビー小体型認知症、パーキンソン病認知症、アルツハイマー病、血管性認知症、その他）、薬剤クラス別（コリンエステラーゼ阻害剤、NMDA拮抗薬＆その配合剤）、流通チャネル別（小売薬局、病院薬局、オンライン薬局）、地域別
  • 世界の神経変性治療薬市場2021年-2031年：薬物クラス別（ドパミン作動薬、脱炭酸酵素阻害薬、コリンエステラーゼ阻害薬、免疫調節薬、その他）、疾患別（パーキンソン病、アルツハイマー病、多発性硬化症、その他）、流通チャネル別（病院薬局、オンラインプロバイダー、ドラッグストア・小売薬局）
  • 経口抗ウィルス薬のグローバル市場（2021-2031）：肝炎、ヒト免疫不全ウイルス（HIV）、インフルエンザ、その他
  • 抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬
  • 治療薬物モニタリング（TDM）のグローバル市場（2021-2031）：消耗品、装置
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB162 )"認知症治療薬のグローバル市場（2021〜2031）：レビー小体型認知症、パーキンソン病認知症、アルツハイマー病、血管性認知症、その他" (英文：Dementia Drugs Market By Indication (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), By Drug Class (Cholinesterase Inhibitors, NMDA Antagonists and its Combination Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。